JP2015505565A5 - - Google Patents

Download PDF

Info

Publication number
JP2015505565A5
JP2015505565A5 JP2014555783A JP2014555783A JP2015505565A5 JP 2015505565 A5 JP2015505565 A5 JP 2015505565A5 JP 2014555783 A JP2014555783 A JP 2014555783A JP 2014555783 A JP2014555783 A JP 2014555783A JP 2015505565 A5 JP2015505565 A5 JP 2015505565A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
cobicistat
acceptable salt
kit
tenofovir arafenamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014555783A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015505565A (ja
JP6059255B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/024438 external-priority patent/WO2013116720A1/en
Publication of JP2015505565A publication Critical patent/JP2015505565A/ja
Publication of JP2015505565A5 publication Critical patent/JP2015505565A5/ja
Application granted granted Critical
Publication of JP6059255B2 publication Critical patent/JP6059255B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014555783A 2012-02-03 2013-02-01 ウイルス感染の処置における使用のためのテノホビルアラフェンアミドヘミフマル酸塩とコビシスタットを含む併用療法 Active JP6059255B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201261594894P 2012-02-03 2012-02-03
US61/594,894 2012-02-03
US201261618411P 2012-03-30 2012-03-30
US61/618,411 2012-03-30
US201261624676P 2012-04-16 2012-04-16
US61/624,676 2012-04-16
US201261692392P 2012-08-23 2012-08-23
US61/692,392 2012-08-23
US201261737493P 2012-12-14 2012-12-14
US61/737,493 2012-12-14
PCT/US2013/024438 WO2013116720A1 (en) 2012-02-03 2013-02-01 Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections

Publications (3)

Publication Number Publication Date
JP2015505565A JP2015505565A (ja) 2015-02-23
JP2015505565A5 true JP2015505565A5 (enExample) 2016-03-24
JP6059255B2 JP6059255B2 (ja) 2017-01-11

Family

ID=47722563

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014555783A Active JP6059255B2 (ja) 2012-02-03 2013-02-01 ウイルス感染の処置における使用のためのテノホビルアラフェンアミドヘミフマル酸塩とコビシスタットを含む併用療法

Country Status (15)

Country Link
US (2) US20150105350A1 (enExample)
EP (1) EP2809323A1 (enExample)
JP (1) JP6059255B2 (enExample)
KR (1) KR20140119177A (enExample)
CN (1) CN104105484A (enExample)
AU (3) AU2013204731C1 (enExample)
BR (1) BR112014018918A8 (enExample)
CA (1) CA2863662A1 (enExample)
EA (1) EA026138B1 (enExample)
HK (2) HK1202801A1 (enExample)
IL (1) IL233874A0 (enExample)
MD (1) MD20140091A2 (enExample)
MX (1) MX2014009172A (enExample)
NZ (1) NZ629896A (enExample)
WO (2) WO2013116730A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3150586T (pt) 2007-02-23 2020-03-31 Gilead Sciences Inc Moduladores de propriedades farmacocinéticas de agentes terapêuticos
UY32306A (es) 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
AP3639A (en) * 2011-08-16 2016-03-13 Gilead Sciences Inc Tenofovir alafenamide hemifumarate
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
HK1220390A1 (zh) * 2013-08-29 2017-05-05 Teva Pharmaceutical Industries Ltd. 包括恩曲他滨，替诺福韦，达芦那韦和利托那韦的单位剂型以及包含达芦那韦和利托那韦的单体片剂
IN2013CH05455A (enExample) * 2013-11-27 2015-08-07 Laurus Labs Private Ltd
US9463194B2 (en) 2014-02-05 2016-10-11 Gilead Sciences, Inc. Methods of treating patients co-infected with HIV and tuberculosis
EP3129009A1 (en) * 2014-04-08 2017-02-15 Teva Pharmaceutical Industries Ltd Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
CN105518011B (zh) * 2014-04-21 2018-07-27 四川海思科制药有限公司 氨基磷酸酯类衍生物制备方法及其中间体和中间体的制备方法
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
SI3166607T1 (sl) * 2014-07-11 2023-01-31 Gilead Sciences, Inc. Modulatorji toličnih receptorjev za zdravljenje HIV-a
CN110305133A (zh) 2014-09-16 2019-10-08 吉利德科学公司 Toll样受体调节剂的固体形式
CN105237571B (zh) * 2014-11-28 2018-03-09 成都苑东生物制药股份有限公司 9‑[(r)‑2‑[[(s)‑[[(s)‑1‑(异丙氧基羰基)乙基]氨基]苯氧基氧膦基]甲氧基]丙基]腺嘌呤的盐
JP2017536403A (ja) * 2014-12-04 2017-12-07 アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． デルタ肝炎ウイルス感染の治療
WO2016106050A1 (en) 2014-12-26 2016-06-30 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
AU2015373104B2 (en) * 2015-01-03 2020-07-09 Mylan Laboratories Limited Processes for the preparation of amorphous tenofovir alafenamide hemifumarate and a premix thereof
HUE054068T2 (hu) 2015-04-21 2021-08-30 Eiger Biopharmaceuticals Inc Lonafarnibot és Ritonavirt tartalmazó gyógyszerkészítmények
CN104817593B (zh) * 2015-04-27 2016-11-16 广州同隽医药科技有限公司 半富马酸替诺福韦艾拉酚胺关键中间体的合成工艺
EP4233846B1 (en) * 2015-06-30 2024-12-04 Gilead Sciences, Inc. Pharmaceutical formulations
CA2921336A1 (en) * 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
US9598459B2 (en) 2015-08-03 2017-03-21 Pop Test Oncology Llc Pharmaceutical compositions and methods
CN105153231A (zh) * 2015-08-28 2015-12-16 浙江车头制药股份有限公司 一种一苯基pmpa的制备方法
CN113546052A (zh) 2015-11-09 2021-10-26 吉利德科学公司 治疗人免疫缺陷病毒的治疗组合物
AU2017218800B2 (en) * 2016-02-12 2022-09-22 Cipla Limited Pharmaceutical compositions comprising an anti-retroviral drug and a pharmacokinetic enhancer
CN107179355B (zh) * 2016-03-11 2021-08-10 广东东阳光药业有限公司 一种分离检测替诺福韦艾拉酚胺及其有关物质的方法
WO2018039157A1 (en) * 2016-08-25 2018-03-01 Merck Sharp & Dohme Corp. Antiviral prodrugs of tenofovir
CN108070003A (zh) * 2016-12-02 2018-05-25 上海博志研新药物技术有限公司 替诺福韦艾拉酚胺半反丁烯二酸盐晶型及制备方法和应用
RU2659388C1 (ru) 2017-02-28 2018-07-02 Васильевич Иващенко Александр Нуклеотиды, включающие N-[(S)-1-циклобутоксикарбонил]фосфорамидатный фрагмент, их аналоги и их применение
RU2647576C1 (ru) * 2017-02-28 2018-03-16 Васильевич Иващенко Александр Циклобутил (S)-2-[[[(R)-2-(6-аминопурин-9-ил)-1-метил-этокси]метил-фенокси-фосфорил]амино]-пропаноаты, способ их получения и применения
CN106928277A (zh) * 2017-03-16 2017-07-07 江苏诚信药业有限公司 一种替诺福韦艾拉酚胺合成的工艺方法
US11191763B2 (en) 2017-03-20 2021-12-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services HIV post-exposure prophylaxis
RU2019136678A (ru) * 2017-04-18 2021-05-18 Сипла Лимитед Комбинированная терапия для применения в лечении ретровирусных инфекций
RU2659693C1 (ru) * 2017-06-30 2018-07-03 Общество с ограниченной ответственностью "Изварино Фарма" Фармацевтическая композиция, обладающая активностью против ВИЧ-инфекции
EP3700573A1 (en) * 2017-10-24 2020-09-02 Gilead Sciences, Inc. Methods of treating patients co-infected with a virus and tuberculosis
RU2020116571A (ru) 2017-12-07 2021-11-22 Эмори Юниверсити N4-гидроксицитидин и производные и связанные с этим противовирусные применения
CN110305163A (zh) * 2018-03-27 2019-10-08 北京济美堂医药研究有限公司 替诺福韦艾拉酚胺半富马酸盐的制备方法
CN108484672A (zh) * 2018-05-23 2018-09-04 中国药科大学制药有限公司 磷丙替诺福韦的手性拆分方法
CN109081853A (zh) * 2018-09-03 2018-12-25 南京正大天晴制药有限公司 一种磷丙替诺福韦有关物质的制备方法
CN113924114A (zh) 2019-05-22 2022-01-11 吉利德科学公司 Tlr7调节化合物和hiv疫苗的组合
EP3989956A1 (en) * 2019-06-28 2022-05-04 Anhui Ronghang Biotech Development Co., Ltd. Compositions and methods for treatment of hepatitis b virus infection
AU2020318808A1 (en) 2019-07-19 2022-02-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HIV pre-exposure prophylaxis
CN111606949A (zh) * 2020-03-13 2020-09-01 浙江车头制药股份有限公司 一种磷丙替诺福韦杂质的制备方法
CN111303209A (zh) * 2020-03-21 2020-06-19 石家庄龙泽制药股份有限公司 一种丙酚替诺福韦降解杂质的制备方法
US20240009214A1 (en) * 2020-12-02 2024-01-11 Cipla Limited Method of Treating Viral Infection
WO2024196814A1 (en) 2023-03-17 2024-09-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for treatment of age-related macular degeneration
EP4640214A1 (en) * 2024-03-28 2025-10-29 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A tablet comprising tenofovir alafenamide monofumarate

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB453061A (en) 1935-03-23 1936-09-04 Charles Howard Twigg Improvements in and relating to gas heated geysers and water heaters
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
HRP20030047B1 (hr) 2000-07-21 2016-02-26 Gilead Sciences, Inc. Prolijekovi koji su fosfonatni analozi nukleotida i metode njihovog odabira te njihova priprava
DE10153078A1 (de) 2001-10-30 2003-05-22 Degussa Verwendung von Granulaten auf Basis von pyrogen hergestelltem Siliciumdioxid in pharmazeutischen Zusammensetzungen
PT1583542E (pt) 2003-01-14 2008-09-17 Gilead Sciences Inc Composições e métodos para terapia de combinação antiviral
PT3150586T (pt) * 2007-02-23 2020-03-31 Gilead Sciences Inc Moduladores de propriedades farmacocinéticas de agentes terapêuticos
US8354421B2 (en) 2007-06-29 2013-01-15 Korea Research Insitute Of Chemical Technology HIV reverse transcriptase inhibitors
PL2393485T3 (pl) * 2009-02-06 2015-12-31 Gilead Sciences Inc Dwuwarstwowe tabletki zawierające elwitegrawir, kobicystat, emtrycytabinę i tenofowir
AP3639A (en) * 2011-08-16 2016-03-13 Gilead Sciences Inc Tenofovir alafenamide hemifumarate

Similar Documents

Publication Publication Date Title
JP2015038149A5 (enExample)
JP2016508134A5 (enExample)
HRP20231018T1 (hr) Terapeutski spojevi korisni za profilaktičko ili terapijsko liječenje hiv virusne infekcije
HRP20191957T1 (hr) Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba
WO2017083304A8 (en) Therapeutic compositions for treatment of human immunodeficiency virus
JP2016179996A5 (enExample)
JP2010532372A5 (enExample)
HRP20240501T1 (hr) Derivati pirido[2,3-d]pirimidina kao inhibitori replikacije virusa humane imunodeficijencije
HRP20211543T1 (hr) Derivati kinazolina koji se koriste za liječenje hiv-a
HRP20180455T1 (hr) Natrijev (2r, 5s, 13ar) -7, 9-diokso-10- ( (2,4,6-trifluorobenzil) karbamoil) -2, 3, 4, 5, 7, 9, 13, 13a-oktahidro-2, 5-metanopirido [1’,2’ : 4.5]pirazino [2,1-b]oksazepin-8-olat
JP2016527217A5 (enExample)
JP2013518124A5 (enExample)
JP2015522018A5 (enExample)
RU2013148779A (ru) Лечение инфекции вируса гепатита в по отдельности или в комбинации с вирусом гепатита дельта и родственных заболеваний печени
JP2017514911A5 (enExample)
JP2002528502A5 (enExample)
JP2017503014A5 (enExample)
JP2013508289A5 (enExample)
JP2016505050A5 (enExample)
JP2023531930A5 (enExample)
WO2006044968A3 (en) Combination therapy for treating viral infections
EP4230209A4 (en) PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL COMBINED FORMULATION AND COMBINATION FORMULATION KIT FOR THE PREVENTION OR TREATMENT OF CHRONIC HEPATITIS B, EACH COMPRISING, AS ACTIVE INGREDIENT, AN ORAL ANTIVIRAL AGENT AND A THERAPEUTIC VACCINE COMPRISING A LIPOPEPTIDE AND A POLY(I) ADJUVANT :VS)
JP2015515971A5 (enExample)
WO2012047993A3 (en) N-hydroxypyrimidine-2,4-diones as inhibitors of hiv and hcv
PH12014501601A1 (en) Artemisinin-based combination therapy for treating viral mediated disease